ctDNA在结直肠癌诊疗中的应用

Abstract
Figure/Table
References (44)
Related Citation (15)

Download: PDF (557 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Colorectal cancer is the fifth leading cause of death among malignancies in China. Screening methods for colorectal cancer are of great significance for early diagnosis, selection of targeted drugs and immunotherapy and prognosis. With the continuous development of high-throughput sequencing technology and tumor genomics, circulating tumor DNA (ctDNA) detection technology has been widely used and studied in clinic due to its non-invasive and high specificity. The methylation level, mutation and copy number variation of colorectal cancer related genes detected by ctDNA can achieve early screening effect. ctDNA detection of RAS, HER2 and other target genes plays an important guiding role in individualized medication and prognosis monitoring of patients. In this review, the recent advances in the application of ctDNA in the early screening, treatment and prognosis of colorectal cancer are reviewed.

Key words： Circulating tumor DNA Colorectal cancer Early screen Diagnosis and treatment Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Li JIANG Ping▲ GE Wei

Cite this article:

LIU Li JIANG Ping▲ GE Wei. Application of ctDNA in the diagnosis and treatment of colorectal cancer[J]. 中国医药导报, 2021, 18(21): 33-37.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I21/33

[1] Els W，Schreuders EH，Grobbee EJ，et al. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening：a systematic review and meta-analysis [J]. Gut，2019，68（5）：873-881.
[2] Ng SB，Chua C，Ng M，et al. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery [J]. Sci Rep，2017，7：40737.
[3] Diaz LA，Bardelli A. Liquid biopsies：genotyping circulating tumor DNA [J]. J Clin Oncol，2014，32（6）：579-586.
[4] Siegel RL，Miller KD，Sauer AG，et al. Colorectal cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（3）：145-164.
[5] Zhang L，Cao F，Zhang G，et al. Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025 [J]. Front Oncol，2019，9：98.
[6] Rawla P，Sunkara T，Barsouk A. Epidemiology of colorectal cancer：Incidence，mortality，survival，and risk factors [J]. Prz Gastroenterol，2019，14（2）：89-103.
[7] Chen H，Li N，Ren J，et al. Participation and yield of a population-based colorectal cancer screening programme in China [J]. Gut，2019，68（8）：1450-1457.
[8] Pinsky PF，Schoen RE. Contribution of surveillance colo-noscopy to colorectal cancer prevention [J]. Clin Gastroenterol Hepatol，2020，18（13）：2937-2944.e1.
[9] Barbany G，Arthur C，Lieden A，et al. Cell-free tumor DNA testing for early detection of cancer-a potential future tool [J]. J Intern Med，2019，286（2）：118-136.
[10] Marcuello M，Vymetalkova V，Neves RPL，et al. Circulating biomarkers for early detection and clinical management of colorectal cancer [J]. Mol Aspects Med，2019， 69：107-122.
[11] Chen Y，Wang Z，Zhao G，et al. Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test [J]. Dis Markers，2019，2019：5232780.
[12] Symonds EL，Pedersen SK，Murray DH，et al. Circulating tumor DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation，cancer characteristics and surgical resection [J]. Clinical Trial，2018，10：63.
[13] Garrigou S，Perkins G，Garlan F，et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker [J]. Clin Chem，2016，62（8）：1129-1139.
[14] Sun J，Fei F，Zhang M，et al. The role of m SEPT9 in screening，diagnosis，and recurrence monitoring of colorectal cancer [J]. BMC Cancer，2019，19（1）：450.
[15] Hariharan R，Jenkins M. Utility of the methylated SEPT9 test for the early detection of colorectal cancer：a systematic review and meta-analysis of diagnostic test accuracy [J]. BMJ Open Gastroenterol，2020，7（1）：e000355.
[16] Luo H，Zhao Q，Wei W，et al. Circulating tumor DNA methylation profiles enable early diagnosis，prognosis prediction，and screening for colorectal cancer [J]. Sci Transl Med，2020，12（524）：eaax7533.
[17] T?覿nzer M，Balluff B，Distler J，et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions [J]. PLoS One，2010，5（2）：e9061.
[18] Zhao G，Li H，Yang Z，et al. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening [J]. Cancer Med，2019，8（12）：5619-5628.
[19] Zhao G，Ma Y，Li H，et al. A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2 [J]. Clin Chim Acta，2020，503：84-89.
[20] Jensen S?覫，?覫gaard N，?覫rntoft MBW，et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study [J]. Clin Epigenetics，2019，11（1）：158.
[21] Zeng C，Stroup EK，Zhang Z，et al. Towards precision medicine：advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy [J]. Cancer Commun（Lond），2019，39（1）：12.
[22] Li WS，Zhang X，Lu XY，et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers [J]. Cell Res，2017，27（10）：1243-1257.
[23] Xiao ZW，Wu W，Wu C，et al. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma [J]. Mol Oncol，2021，15（1）：138-150.
[24] Cohen JD，Li L，Wang Y，et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test [J]. Science，2018，359（6378）：926-930.
[25] Xu JF，Kang Q，Ma XY，et al. A novel method to detect early colorectal cancer based on chromosome copy number variation in plasma [J]. Cell Physiol Biochem，2018， 45（4）：1444-1454.
[26] Suzuki T，Suzuki T，Yoshimura Y，et al. Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers [J]. Oncotarget，2020，11（34）：3198-3207.
[27] Hendricks A，Rosenstiel P，Hinz S，et al. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy：a case report of use of liquid biopsy [J]. BMC Med Genet，2020，21（1）：3.
[28] Lakatos G，K?觟hne CH，Bodoky G. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status [J]. Cancer Metastasis Rev，2020，39（4）：1143-1157.
[29] Douillard JY，Oliner KS，Siena S，et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer [J]. N Engl J Med，2013，369（11）：1023-1034.
[30] Johnson B，Kopetz S. Applying precision to the management of BRAF-mutant metastatic colorectal cancer [J]. Target Oncol，2020，15（5）：567-577.
[31] Ye S，Hu X，Ni C，et al. KLF4 p.A472D mutation contributes to acquired resistance to cetuximab in colorectal cancer [J]. Mol Cancer Ther，2020，19（3）：956-965.
[32] Russo M，Misale S，Wei G，et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer [J]. Cancer Discov，2016，6（1）：36-44.
[33] Osumi H，Shinozaki E，Yamaguchi K. Circulating tumor DNA as a novel biomarker optimizing chemotherapy for colorectal cancer [J]. Cancers（Basel），2020，12（6）：1566.
[34] Evrard C，Tachon G，Randrian V，et al. Microsatellite instability：diagnosis，heterogeneity，discordance，and clinical impact in colorectal cancer [J]. Cancers（Basel），2019， 11（10）：1567.
[35] Jácome AA，Eng C. Role of immune checkpoint inhibitors in the treatment of colorectal cancer：focus on nivolumab [J]. Expert Opin Biol Ther，2019，19（12）：1247-1263.
[36] Diehl F，Schmidt K，Choti MA，et al. Circulating mutant DNA to assess tumor dynamics [J]. Nat Med，2008，14（9）：985-990.
[37] Symonds EL，Pedersen SK，Murray D，et al. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer [J]. Cancer，2020，126（7）：1460-1469.
[38] Koncina E，Haan S，Rauh S，et al. Prognostic and predictive molecular biomarkers for colorectal cancer：Updates and challenges [J]. Cancers（Basel），2020，12（2）：319.
[39] Auclin E，Zaanan A，Vernerey D，et al. Subgroups and prognostication in stage Ⅲ colon cancer：future perspectives for adjuvant therapy [J]. Ann Oncol，2017，28（5）：958-968.
[40] Amatu A，Schirripa M，Tosi F，et al. High circulating methylated DNA is a negative predictive and prognostic marker in metastatic colorectal cancer patients treated with regorafenib [J]. Front Oncol，2019，9：622.
[41] Ardekani GS，Jafarnejad SM，Tan L，et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma：a systematic review and meta-analysis [J]. PLoS One，2012，7（10）：e47054.
[42] Osumi H，Shinozaki E，Yamaguchi K，et al. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer [J]. Sci Rep，2019，9（1）：17358.
[43] Bouchahda M，Saffroy R，Karaboué A，et al. Undetectable RAS-mutant clones in plasma：possible implication for anti-EGFR therapy and prognosis in patients with RAS-mutant metastatic colorectal cancer [J]. JCO Precis Oncol，2020，4：PO.19.00400.
[44] Misale S，Yaeger R，Hobor S，et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer [J]. Nature，2012，486（7404）：532-536.